{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:15:32Z","timestamp":1791173732811,"version":"4.1.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2004,5,17]],"date-time":"2004-05-17T00:00:00Z","timestamp":1084752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In-transit metastases from cutaneous malignant melanoma (cutaneous or subcutaneous deposits between the primary melanoma and regional lymph nodes) represent late-stage disease, and their treatment should be tailored accordingly. This article reviews the pathology, clinical significance and treatment options for in-transit disease from melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An initial Medline search was undertaken using the keywords \u2018melanoma and in-transit\u2019 and \u2018melanoma and non-nodal regional recurrence\u2019. Additional original articles were obtained from citations in articles identified by the initial search.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and conclusion<\/jats:title>\n                  <jats:p>In-transit metastases carry a poor prognosis. The method of treatment should be tailored to the extent of cutaneous disease. The first line of treatment remains complete excision with negative histopathological margins. There is no need for wide excision. Carbon dioxide laser therapy is valuable for multiple small cutaneous deposits. Isolated limb perfusion has a role for numerous or bulky advanced in-transit metastases in the limbs that are beyond the scope of simpler techniques. Systemic chemotherapy has response rates of about 25 per cent and is reserved for patients for whom surgery is no longer feasible.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.4610","type":"journal-article","created":{"date-parts":[[2004,5,17]],"date-time":"2004-05-17T17:01:01Z","timestamp":1084813261000},"page":"673-682","source":"Crossref","is-referenced-by-count":61,"title":["Management of in-transit metastases from cutaneous malignant melanoma"],"prefix":"10.1093","volume":"91","author":[{"given":"A J","family":"Hayes","sequence":"first","affiliation":[{"name":"Sarcoma and Melanoma Unit, Department of Surgery, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Clark","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Department of Surgery, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Harries","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Department of Surgery, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,5,17]]},"reference":[{"key":"2021070907235411800_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"2021070907235411800_bib2","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1046\/j.1365-2168.2000.01439.x","article-title":"Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma","volume":"87","author":"Hughes","year":"2000","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1365-2168.1999.01316.x","article-title":"Combined inguinal and pelvic lymph node dissection for stage III melanoma","volume":"86","author":"Hughes","year":"1999","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1445-2197.2002.02376.x","article-title":"Melanoma: Margins for error\u2014another view","volume":"72","author":"McCarthy","year":"2002","journal-title":"Aust NZ J Surg"},{"key":"2021070907235411800_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1054\/bjps.1998.3050","article-title":"The pathogenesis of local recurrence of melanoma at the primary excision site","volume":"52","author":"Heenan","year":"1999","journal-title":"Br J Plast Surg"},{"key":"2021070907235411800_bib7","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib8","first-page":"65","article-title":"Molecular aspects of the metastatic cascade","volume":"989","author":"Hart","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"2021070907235411800_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Fidler","year":"1994","journal-title":"Cell"},{"key":"2021070907235411800_bib10","first-page":"175","article-title":"Regional non-nodal metastases of cutaneous melanoma","volume":"12","author":"Cascinelli","year":"1986","journal-title":"Eur J Surg Oncol"},{"key":"2021070907235411800_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-198412000-00015","article-title":"The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma","volume":"200","author":"Kelly","year":"1984","journal-title":"Ann Surg"},{"key":"2021070907235411800_bib12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1997.15.3.1039","article-title":"Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system","volume":"15","author":"Buzaid","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1097-0142(19880401)61:7<1437::AID-CNCR2820610726>3.0.CO;2-Z","article-title":"Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma","volume":"61","author":"Singletary","year":"1988","journal-title":"Cancer"},{"key":"2021070907235411800_bib14","first-page":"262","article-title":"Survival with regional and distant metastases from cutaneous malignant melanoma","volume":"172","author":"Roses","year":"1991","journal-title":"Surg Gynecol Obstet"},{"key":"2021070907235411800_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.1992.373","article-title":"The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2495 patients","volume":"66","author":"Haffner","year":"1992","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib16","first-page":"111","article-title":"Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion","volume":"164","author":"Sutherland","year":"1987","journal-title":"Surg Gynecol Obstet"},{"key":"2021070907235411800_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/1097-0142(19830801)52:3<575::AID-CNCR2820520333>3.0.CO;2-6","article-title":"Prognostic parameters in recurrent malignant melanoma","volume":"52","author":"Karakousis","year":"1983","journal-title":"Cancer"},{"key":"2021070907235411800_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archsurg.1984.01390180011002","article-title":"Local cutaneous recurrence after conservative excision of malignant melanoma","volume":"119","author":"Aitken","year":"1984","journal-title":"Arch Surg"},{"key":"2021070907235411800_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00000658-198307000-00013","article-title":"Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma","volume":"198","author":"Roses","year":"1983","journal-title":"Ann Surg"},{"key":"2021070907235411800_bib20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/1097-0142(19850315)55:6<1398::AID-CNCR2820550639>3.0.CO;2-A","article-title":"The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma","volume":"55","author":"Urist","year":"1985","journal-title":"Cancer"},{"key":"2021070907235411800_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00006534-198805000-00007","article-title":"A comparison of local recurrence and resection margins for stage I primary cutaneous malignant melanomas","volume":"81","author":"Zeitels","year":"1988","journal-title":"Plast Reconstr Surg"},{"key":"2021070907235411800_bib22","first-page":"7","article-title":"A policy of selective excision for primary cutaneous malignant melanoma","volume":"11","author":"Taylor","year":"1985","journal-title":"Eur J Surg Oncol"},{"key":"2021070907235411800_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/1097-0142(197903)43:3<883::AID-CNCR2820430316>3.0.CO;2-V","article-title":"Tumor thickness as a guide to surgical management of clinical stage I melanoma patients","volume":"43","author":"Balch","year":"1979","journal-title":"Cancer"},{"key":"2021070907235411800_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/bjs.1800730507","article-title":"Incidence of locally metastatic (\u2018recurrent\u2019) cutaneous malignant melanoma following conventional wide margin excisional surgery for invasive clinical stage I tumours: importance of maximal primary tumour thickness","volume":"73","author":"Griffiths","year":"1986","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bjc.1984.137","article-title":"Cutaneous malignant melanoma in West Yorkshire: II. A prospective study of recurrence and prediction of lymph nodal metastasis","volume":"50","author":"Eastwood","year":"1984","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib26","first-page":"79","article-title":"Some views on the treatment of melanomas of the skin","volume":"22","author":"Olsen","year":"1970","journal-title":"Arch Chir Neerl"},{"key":"2021070907235411800_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1524-4725.1995.tb00174.x","article-title":"The prognosis and treatment of true local cutaneous recurrent malignant melanoma","volume":"21","author":"Brown","year":"1995","journal-title":"Dermatol Surg"},{"key":"2021070907235411800_bib28","first-page":"92","article-title":"On a case of multiple melanotic sarcoma, with remarks on the mode of growth and extension of such tumours","volume":"24","author":"Coats","year":"1885","journal-title":"Glasgow Med J"},{"key":"2021070907235411800_bib29","volume-title":"Eight Cases of Melanosis with Pathological and Therapeutic Remarks on That Disease","author":"Norris","year":"1857"},{"key":"2021070907235411800_bib30","first-page":"996","article-title":"The pathology of melanotic growths in relation to their operative treatment","volume":"i","author":"Handley","year":"1907","journal-title":"Lancet"},{"key":"2021070907235411800_bib31","first-page":"1","article-title":"The malignant melanoma of the skin. New theories based on a study of 500 cases","volume":"365","author":"Olsen","year":"1966","journal-title":"Acta Chir Scand Suppl"},{"key":"2021070907235411800_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","article-title":"Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3cm","volume":"318","author":"Veronesi","year":"1988","journal-title":"N Engl J Med"},{"key":"2021070907235411800_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/(SICI)1098-2388(199806)14:4<272::AID-SSU2>3.0.CO;2-#","article-title":"Margin of resection in the management of primary melanoma","volume":"14","author":"Cascinelli","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"2021070907235411800_bib34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","article-title":"Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0\u00b78\u20132 \u00b70 mm","volume":"89","author":"Cohn-Cedermark","year":"2000","journal-title":"Cancer"},{"key":"2021070907235411800_bib35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00000658-199309000-00005","article-title":"Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial","volume":"218","author":"Balch","year":"1993","journal-title":"Ann Surg"},{"key":"2021070907235411800_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2133.2001.04614.x","article-title":"UK guidelines for the management of cutaneous melanoma","volume":"146","author":"Roberts","year":"2002","journal-title":"Br J Dermatol"},{"key":"2021070907235411800_bib37","volume-title":"Guidelines for the Management of Cutaneous Melanoma","author":"Australian Cancer Network","year":"1997"},{"key":"2021070907235411800_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa030681","article-title":"Excision margins in high-risk melanoma","volume":"350","author":"Thomas","year":"2004","journal-title":"New Engl J Med"},{"key":"2021070907235411800_bib39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1445-2197.2002.02375.x","article-title":"Melanoma: margins for error","volume":"72","author":"Heenan","year":"2002","journal-title":"Aust NZ J Surg"},{"key":"2021070907235411800_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1445-2197.2002.02374.x","article-title":"Surgical margins for melanoma: is 2 cm too much?","volume":"72","author":"Balch","year":"2002","journal-title":"Aust NZ J Surg"},{"key":"2021070907235411800_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0007-1226(73)90040-4","article-title":"The carbon dioxide laser in plastic surgery","volume":"26","author":"Kaplan","year":"1973","journal-title":"Br J Plast Surg"},{"key":"2021070907235411800_bib42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/bjs.1800670506","article-title":"Impairment of skin graft take after CO2 laser surgery in melanoma patients","volume":"67","author":"Lejeune","year":"1980","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/000348948109000403","article-title":"Carbon dioxide laser treatment of metastatic melanoma of the trachea and bronchi","volume":"90","author":"Andrews","year":"1981","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2021070907235411800_bib44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1288\/00005537-198507000-00009","article-title":"Palliative laser surgery for melanoma metastatic to the larynx: report of two cases","volume":"95","author":"Morgan","year":"1985","journal-title":"Laryngoscope"},{"key":"2021070907235411800_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/bjs.1800780433","article-title":"Carbon dioxide laser ablation of cutaneous metastases from malignant melanoma","volume":"78","author":"Waters","year":"1991","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib46","first-page":"173","article-title":"Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser","volume":"19","author":"Hill","year":"1993","journal-title":"Eur J Surg Oncol"},{"key":"2021070907235411800_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/bjs.1800830425","article-title":"Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma","volume":"83","author":"Hill","year":"1996","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib48","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/bjs.1800821016","article-title":"Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma","volume":"82","author":"Lingam","year":"1995","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib49","first-page":"1885","article-title":"Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities","volume":"45","author":"Briele","year":"1985","journal-title":"Cancer Res"},{"key":"2021070907235411800_bib50","first-page":"938","article-title":"Techniques of regional perfusion","volume":"60","author":"Creech","year":"1966","journal-title":"Surgery"},{"key":"2021070907235411800_bib51","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2021070907235411800_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2106\/00004623-197759020-00008","article-title":"Double-incision fasciotomy of the leg for decompression in compartment syndromes","volume":"59A","author":"Mubarak","year":"1977","journal-title":"J Bone Joint Surg (US)"},{"key":"2021070907235411800_bib53","first-page":"305","article-title":"Hyperthermic perfusion with chemotherapy for cancers of the extremities","volume":"129","author":"Stehlin","year":"1969","journal-title":"Surg Gynecol Obstet"},{"key":"2021070907235411800_bib54","first-page":"339","article-title":"Results of hyperthermic perfusion for melanoma of the extremities","volume":"140","author":"Stehlin","year":"1975","journal-title":"Surg Gynecol Obstet"},{"key":"2021070907235411800_bib55","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9610(94)90111-2","article-title":"Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities","volume":"167","author":"Klaase","year":"1994","journal-title":"Am J Surg"},{"key":"2021070907235411800_bib56","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/sonc.2002.34119","article-title":"Isolated limb perfusion in locally advanced cutaneous melanoma","volume":"29","author":"Rossi","year":"2002","journal-title":"Semin Oncol"},{"key":"2021070907235411800_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1245\/aso.2002.9.2.127","article-title":"Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma","volume":"9","author":"Lindner","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"2021070907235411800_bib58","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1200\/JCO.1998.16.9.2906","article-title":"Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18 832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593","volume":"16","author":"Koops","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00001813-199902000-00014","article-title":"Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)","volume":"10","author":"Hochster","year":"1999","journal-title":"Anticancer Drugs"},{"key":"2021070907235411800_bib60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/bjs.1800670919","article-title":"Isolated limb perfusion with melphalan in the treatment of malignant melanoma","volume":"67","author":"Bulman","year":"1980","journal-title":"Br J Surg"},{"key":"2021070907235411800_bib61","first-page":"39","article-title":"Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan","volume":"115","author":"Klaase","year":"1994","journal-title":"Surgery"},{"key":"2021070907235411800_bib62","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/1097-0142(19890615)63:12<2551::AID-CNCR2820631233>3.0.CO;2-7","article-title":"Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion","volume":"63","author":"Di Filippo","year":"1989","journal-title":"Cancer"},{"key":"2021070907235411800_bib63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/978-3-642-82025-0_45","article-title":"Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan","volume":"86","author":"Lejeune","year":"1983","journal-title":"Recent Results Cancer Res"},{"key":"2021070907235411800_bib64","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0959-8049(97)00358-4","article-title":"Management of cutaneous melanoma M0: state of the art and trends","volume":"33","author":"Rossi","year":"1997","journal-title":"Eur J Cancer"},{"key":"2021070907235411800_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-3-642-82025-0_40","article-title":"Regional perfusion with cis-platinum and dacarbazine","volume":"86","author":"Aigner","year":"1983","journal-title":"Recent Results Cancer Res"},{"key":"2021070907235411800_bib66","first-page":"127","article-title":"Hyperthermic antiblastic perfusion with DTIC in stage IIIA\u2013IIIAB melanoma of the extremities","volume":"13","author":"Vaglini","year":"1987","journal-title":"Eur J Surg Oncol"},{"key":"2021070907235411800_bib67","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0011-3840(99)80008-2","article-title":"Hyperthermic regional perfusion for melanoma and sarcoma of the limbs","volume":"36","author":"Fraker","year":"1999","journal-title":"Curr Probl Surg"},{"key":"2021070907235411800_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J Clin"},{"key":"2021070907235411800_bib69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00000421-199904000-00017","article-title":"Role of radiation therapy in the management of cutaneous malignant melanoma","volume":"22","author":"Fenig","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"2021070907235411800_bib70","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","article-title":"Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience","volume":"44","author":"Seegenschmiedt","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070907235411800_bib71","first-page":"363","volume-title":"Cancer Principles and Practice of Oncology","author":"Colvin","year":"2001","edition":"6th"},{"key":"2021070907235411800_bib72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib73","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/sonc.2002.35237","article-title":"Systemic chemotherapy for the treatment of metastatic melanoma","volume":"29","author":"Li","year":"2002","journal-title":"Semin Oncol"},{"key":"2021070907235411800_bib74","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib75","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1054\/bjoc.1999.1056","article-title":"A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma","volume":"82","author":"Middleton","year":"2000","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib76","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.1999.17.6.1884","article-title":"Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma","volume":"17","author":"Creagan","year":"1999","journal-title":"J Clin"},{"key":"2021070907235411800_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200104000-00015","article-title":"Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients","volume":"11","author":"Chiarion Sileni","year":"2001","journal-title":"Melanoma Res"},{"key":"2021070907235411800_bib78","first-page":"361a","article-title":"Complete remission of metastatic melanoma after treatment with the dartmouth regimen","volume":"20","author":"Zrada","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021070907235411800_bib79","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1994.12.8.1553","article-title":"Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma","volume":"12","author":"Atkins","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib80","first-page":"708","article-title":"A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial","volume":"22","author":"Atkins","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021070907235411800_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","article-title":"Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)","volume":"86","author":"Atzpodien","year":"2002","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib82","first-page":"709","article-title":"Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts)","volume":"22","author":"Del Vecchio","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021070907235411800_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1054\/bjoc.2001.1731","article-title":"Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"84","author":"Hauschild","year":"2001","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib84","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.1998.214","article-title":"Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma","volume":"77","author":"Johnston","year":"1998","journal-title":"Br J Cancer"},{"key":"2021070907235411800_bib85","first-page":"708","article-title":"Dacarbazine, cisplatin and IFN-\u03b12b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951","volume":"22","author":"Keilholz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021070907235411800_bib86","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","article-title":"Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b","volume":"17","author":"Rosenberg","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021070907235411800_bib87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000055297","article-title":"Is forequarter amputation justified for palliation of intractable cancer symptoms?","volume":"60","author":"Merimsky","year":"2001","journal-title":"Oncology"},{"key":"2021070907235411800_bib88","first-page":"1","article-title":"Major amputation for advanced malignant melanoma","volume":"169","author":"Jaques","year":"1989","journal-title":"Surg Gynecol Obstet"},{"key":"2021070907235411800_bib89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.12968\/bjcn.2002.7.8.10641","article-title":"Malignant fungating wounds: assessment and management","volume":"7","author":"Dowsett","year":"2002","journal-title":"Br J Community Nurs"},{"key":"2021070907235411800_bib90","first-page":"55","article-title":"Managing patients with fungating malignant wounds","volume":"99","author":"McMurray","year":"2003","journal-title":"Nurs Times"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.4610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/91\/6\/673\/36729430\/bjs4610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/91\/6\/673\/36729430\/bjs4610.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T17:18:51Z","timestamp":1625851131000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/91\/6\/673\/6151167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,17]]},"references-count":90,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2004,5,17]]},"published-print":{"date-parts":[[2004,5,17]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.4610","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,6]]},"published":{"date-parts":[[2004,5,17]]}}}